Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam besylate vs propofol for sedation in critically ill patients undergoing operative examinations
ChiCTR2600122705Phase 4Not yet recruiting
- Sponsor
- Shijiazhuang People's Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and propofol in critical illness (2 arms), sponsored by Shijiazhuang People's Hospital. Primary endpoints: Sedation onset time, Incidence of adverse reactions during the study period and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
remimazolampropofol
03
Conditions
critical illness
Beyond the preview
Go deeper on ChiCTR2600122705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122705.